-
Mashup Score: 0Quality of Life With Nivolumab Plus Chemotherapy in Advanced Gastric/GEJ Cancer or Esophageal Adenocarcinoma - The ASCO Post - 7 month(s) ago
As reported in the Journal of Clinical Oncology, Markus Moehler, MD, and colleagues found that in the phase III CheckMate 649 trial, the addition of nivolumab to chemotherapy was associated with generally better patient-reported health-related quality of life outcomes in patients with advanced non–HER2-positive (HER2-negative or unknown HER2 status) gastric/gastroesophageal junction cancer or esophageal adenocarcinoma. The trial supported the April 2021 approval of nivolumab in combination with fluoropyrim
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma - The ASCO Post - 8 month(s) ago
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel study published by Shah et al in Nature Medicine. Gastric cancer is the fifth most diagnosed cancer type globally, and its incidence has increased significantly over the last few decades. Patients with gastric
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma https://t.co/9yAugI3szn #stcsm #gastriccancer #GEJcancer #oncology
-
-
Mashup Score: 0
Neoadjuvant chemotherapy or chemoradiotherapy improves outcomes in patients with esophageal or gastroesophageal junction cancer, a meta-analysis suggests.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant chemotherapy or chemoradiotherapy improves outcomes in patients with esophageal or gastroesophageal junction cancer. Published in the @JCO_ASCO. https://t.co/bD4XKolmKq #GEJCancer
-
-
Mashup Score: 2Individual Patient Meta-analysis of Neoadjuvant Chemotherapy and Chemoradiotherapy for Esophageal or GEJ Carcinoma - The ASCO Post - 9 month(s) ago
In a meta-analysis reported in the Journal of Clinical Oncology, Faron et al found that neoadjuvant chemotherapy and chemoradiotherapy were associated with better survival vs upfront surgery in patients with thoracic esophageal or gastroesophageal junction (GEJ) carcinoma. The study involved investigation of published or unpublished randomized controlled trials closed to accrual before the end of December 2015 that compared at least two of the following strategies: upfront surgery, chemotherapy followed
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Individual Patient Meta-analysis of Neoadjuvant Chemotherapy and Chemoradiotherapy for Esophageal or GEJ Carcinoma https://t.co/8CoUPkVbjE #esocsm #esophagealcancer #GEJcancer #oncology
-
-
Mashup Score: 1
By Matthew Stenger Posted: 7/11/2023 9:23:00 AM Last Updated: 7/11/2023 11:48:07 AM In a Korean phase Ib/II trial reported in the Journal of Clinical Oncology, Kim et al found that trastuzumab combined with ramucirumab and paclitaxel showed activity in the second-line treatment of patients with HER2-positive…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Second-Line Trastuzumab, Ramucirumab, and Paclitaxel in Previously Treated Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer https://t.co/o9wp0WiOeY #stcsm #gastriccancer #GEJcancer #oncology #immunotherapy
-
-
Mashup Score: 1T-DXd in HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer DESTINY-Gastric02 - The ASCO Post - 10 month(s) ago
By Matthew Stenger Posted: 7/27/2023 12:05:00 PM Last Updated: 6/27/2023 11:36:20 AM In the phase II DESTINY-Gastric02 trial reported in The Lancet Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) was active in patients with HER2-positive advanced gastric…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
T-DXd in HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: DESTINY-Gastric02 https://t.co/oLLJPOdOVB #stcsm #GEJcancer #immunotherapy #oncology
-
-
Mashup Score: 0Adding Cixutumumab to Paclitaxel Does Not Improve Outcomes in Esophageal/GEJ Cancer - 11 month(s) ago
In metastatic esophageal/gastroesophageal junction cancer, the addition of cixutumumab to paclitaxel does not improve outcomes vs paclitaxel alone.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In metastatic esophageal/gastroesophageal junction cancer, the addition of cixutumumab to paclitaxel does not improve outcomes vs paclitaxel alone. Published in @OncJournal and @ONAcom. https://t.co/17PB0pKgtX #GEJCancer
-
-
Mashup Score: 0Adding Cixutumumab to Paclitaxel Does Not Improve Outcomes in Esophageal/GEJ Cancer - 11 month(s) ago
In metastatic esophageal/gastroesophageal junction cancer, the addition of cixutumumab to paclitaxel does not improve outcomes vs paclitaxel alone.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In metastatic esophageal/gastroesophageal junction cancer, the addition of cixutumumab to paclitaxel does not improve outcomes vs paclitaxel alone. Published in @OncJournal. https://t.co/R5Bif9JGLY #GEJCancer
-
-
Mashup Score: 0JNCCN - 1 year(s) ago
JNCCN
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The April issue of @JNCCN is now available online! Featured: @NCCN Guidelines on #EsophagealCancer & #GEJcancer, insights into recent updates to #NCCNGuidelines for #DistressManagement, & more! https://t.co/8t8aPaRYGu #psyonc #esocsm #gastriccancer #esophagogastricjunctioncancer https://t.co/O0eQMoyl82
-
-
Mashup Score: 2Kohei Shitara on Gastric or Gastroesophageal Junction Adenocarcinoma Recent Data on Zolbetuximab Plus mFOLFOX6 - The ASCO Post - 1 year(s) ago
2023 ASCO Gastrointestinal Cancers Symposium Kohei Shitara, MD, of Japan’s National Cancer Center Hospital East, discusses the SPOTLIGHT study’s phase III findings on zolbetuximab plus mFOLFOX6 as first-line treatment for patients with the biomarker claudin-18.2–positive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Kohei Shitara, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Zolbetuximab Plus mFOLFOX6 https://t.co/RCGAJVBdxC #GI23 #GEJcancer #oncology #immunotherapy @KoheiShitara
-
Advanced Gastric and Esophageal Cancer: Quality of Life With Immunochemotherapy https://t.co/2sybdrJhwi #stcsm #esocsm #gastriccancer #esophagealcancer #GEJcancer #oncology #immunotherapy